Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
10 Dec, 20:00
NYSE NYSE
$
206. 54
+6.58
+3.29%
$
500.07B Market Cap
29.06 P/E Ratio
4.96% Div Yield
11,403,316 Volume
9.91 Eps
$ 199.96
Previous Close
Day Range
200.18 206.74
Year Range
140.68 207.81
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 41 days
Johnson & Johnson (JNJ) Q2 2024 Earnings Call Transcript

Johnson & Johnson (JNJ) Q2 2024 Earnings Call Transcript

Johnson & Johnson (NYSE:JNJ ) Q2 2024 Earnings Conference Call July 17, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joe Wolk - Executive Vice President, Chief Financial Officer Joaquin Duato - Chairman and Chief Executive Officer Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Schott - JPMorgan Larry Biegelsen - Wells Fargo Louise Chen - Cantor Fitzgerald Rick Wise - Stifel Terence Flynn - Morgan Stanley Josh Jennings - TD Cowen Dave Risinger - Leerink Partners Danielle Antalffy - UBS Chris Shibutani - Goldman Sachs Joanne Wuensch - Citibank Operator Good morning, and welcome to Johnson & Johnson's Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.

Seekingalpha | 1 year ago
Johnson & Johnson climbs after earnings and revenue beat

Johnson & Johnson climbs after earnings and revenue beat

Johnson & Johnson (NYSE:JNJ) shares climbed 3% after second-quarter earnings fell less than expected.  Helped by 8% sales from its pharmaceutical arm, group revenue rose 4.3% to $22.45 billion, which was above the $22.3 billion Wall Street average forecast.

Proactiveinvestors | 1 year ago
This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum

This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum

Johnson & Johnson NYSE: JNJ has struggled for the last year or two as the impacts of COVID-19 and the spin-off of Kenvue NYSE: KVUE work their way through the system. The takeaway from the Q2 earnings release is that organic growth is back in the picture.

Marketbeat | 1 year ago
Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say

Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 1 year ago
Johnson & Johnson Posts Mixed Earnings, Shifts Full-Year Guidance

Johnson & Johnson Posts Mixed Earnings, Shifts Full-Year Guidance

Johnson & Johnson (JNJ) reported mixed second-quarter results Wednesday, as one-time costs caused the company to miss profit estimates despite better-than-expected sales.

Investopedia | 1 year ago
Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates

Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.82 per share, beating the Zacks Consensus Estimate of $2.71 per share. This compares to earnings of $2.80 per share a year ago.

Zacks | 1 year ago
Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs

Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs

On Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70.

Benzinga | 1 year ago
Johnson & Johnson stock gets a lift from earnings beat, while outlook was mixed

Johnson & Johnson stock gets a lift from earnings beat, while outlook was mixed

Shares of Johnson & Johnson JNJ, +1.19% rose 1.1% in premarket trading Wednesday, after the drug maker beat second-quarter profit and sales expectations, while providing a mixed full-year outlook. Net income fell to $4.69 billion, or $1.93 a share, from $5.14 billion, or $2.05 a share, in the same period a year ago.

Marketwatch | 1 year ago
J&J beats Wall Street estimates on strong drug sales

J&J beats Wall Street estimates on strong drug sales

Johnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara.

Reuters | 1 year ago
Johnson & Johnson Earnings Are Coming. It Took Steps to Put Its Talc Issues Behind It.

Johnson & Johnson Earnings Are Coming. It Took Steps to Put Its Talc Issues Behind It.

ohnson & Johnson is expected to report earnings of $2.71 a share, down slightly from $2.80 from the same period a year ago.

Barrons | 1 year ago
Johnson & Johnson: Bullish Charts Signal Strong Setup Before Q2 Earnings

Johnson & Johnson: Bullish Charts Signal Strong Setup Before Q2 Earnings

Johnson & Johnson JNJ is reporting its second-quarter earnings on Wednesday. Wall Street expects $2.7 in EPS and $22.3 billion in revenues as the company reports before market hours.

Benzinga | 1 year ago
How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings

How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings

Johnson & Johnson JNJ will release its second-quarter financial results, before the opening bell on Wednesday, July 17.

Benzinga | 1 year ago
Loading...
Load More